Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M
Links:
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Acti…
http://ow.ly/kXex50x3CVy
Nov-13-2019
